bullish

Deinove

Implementing the new strategy

50 Views01 Sep 2017 18:50
Issuer-paid
SUMMARY

Deinove has selected key markets of interest, identified strains from its library of bacteria, which indicate suitability for commercial deployment, and formed partnerships to expedite that process. While uncertainties remain, commercial revenues are expected in 2018 and development of revenues in line with our projections would indicate a potential valuation of €4.4/share.

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Logo
Edison Investment Research
Leading International Investment Research
Equities
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x